<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04789954</url>
  </required_header>
  <id_info>
    <org_study_id>UGA 2020-01</org_study_id>
    <nct_id>NCT04789954</nct_id>
  </id_info>
  <brief_title>Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors</brief_title>
  <official_title>An Exploratory Study to Evaluate the Dose Response-Relationship of Pharmacodynamic Parameters of AryoSeven, in Patients With Hemophilia With Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AryoGen Pharmed Co.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AryoGen Pharmed Co.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, single-dose, 5 ways crossover, exploratory clinical trial&#xD;
      evaluating four different doses of AryoSeven (eptacog alfa, activated) and NovoSeven on&#xD;
      selected pharmacodynamic parameters in patients with hemophilia with inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double-blind, single dose, 5 ways crossover, clinical trial evaluating four&#xD;
      different doses (10 µg/kg, 30 µg/kg, 90 µg/kg, and 270 µg/kg) of AryoSeven (recombinant human&#xD;
      FVII activated or eptacog alfa, activated) and one dose of NovoSeven (30 µg/kg) on selected&#xD;
      pharmacodynamic parameters (PD) [Primary: Thrombin Generation Assay (TGA)] in male adult and&#xD;
      adolescent (&gt;12 years) patients with hemophilia A or B, with an inhibitors titer &gt;5 Bethesda&#xD;
      Units [BU] and not in bleeding status. This will be an exploratory study to evaluate&#xD;
      dose-response relationship of PD markers as surrogate efficacy endpoints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lag time of the thrombin generation curve</measure>
    <time_frame>Up to 30 hours after AryoSeven and NovoSeven injection</time_frame>
    <description>Time to 16.7% of peak plasmatic concentration, in minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endogenous Thrombin Potential (PD parameter)</measure>
    <time_frame>Up to 30 hours after AryoSeven and NovoSeven injection</time_frame>
    <description>Area under the curve plasma levels of thrombin generation curve (in nmol/per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak (PD parameter)</measure>
    <time_frame>Up to 30 hours after AryoSeven and NovoSeven injection</time_frame>
    <description>Time to Peak of thrombin generation curve (in minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak height (PD parameter)</measure>
    <time_frame>Up to 30 hours after AryoSeven and NovoSeven injection</time_frame>
    <description>Peak height of thrombin generation curve (in nmol/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>F1.2 prothrombin fragments (PD parameter)</measure>
    <time_frame>Up to 30 hours after AryoSeven and NovoSeven injection</time_frame>
    <description>Peak height (micg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer (PD parameter)</measure>
    <time_frame>Up to 30 hours after AryoSeven and NovoSeven injection</time_frame>
    <description>Peak height (micg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf (PK parameter)</measure>
    <time_frame>Up to 30 hours after AryoSeven and NovoSeven injection</time_frame>
    <description>Area under the plasma concentration time curve from time 0 to infinity, based on the last observed concentration;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (PK parameter)</measure>
    <time_frame>Up to 30 hours after AryoSeven and NovoSeven injection</time_frame>
    <description>Observed maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Cmax (PK parameter)</measure>
    <time_frame>Up to 30 hours after AryoSeven and NovoSeven injection</time_frame>
    <description>Time of observed maximum plasma concentration</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hemophilia A With Inhibitor</condition>
  <condition>Hemophilia B With Inhibitor</condition>
  <arm_group>
    <arm_group_label>AryoSeven 10 μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AryoSeven 30 μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AryoSeven 90 μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AryoSeven 270 μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NovoSeven 30 μg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose, intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Eptacog alfa, activated</intervention_name>
    <description>A dose sequence for each injection will be randomly selected from the following doses: 10 μg/kg, 30 μg/kg, 90 μg/kg, or 270 μg/kg, separated by a wash-out period of 3 days.</description>
    <arm_group_label>AryoSeven 10 μg/kg</arm_group_label>
    <arm_group_label>AryoSeven 270 μg/kg</arm_group_label>
    <arm_group_label>AryoSeven 30 μg/kg</arm_group_label>
    <arm_group_label>AryoSeven 90 μg/kg</arm_group_label>
    <arm_group_label>NovoSeven 30 μg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of congenital haemophilia A or B with inhibitors to FVIII or FIX&#xD;
             titer &gt;5 Bethesda Units [BU]&#xD;
&#xD;
          -  with &gt; 2 episodes of bleeding/year requiring treatment with FVII infusions, not in&#xD;
             bleeding episode&#xD;
&#xD;
          -  Male adults and adolescents (&gt;12 years)&#xD;
&#xD;
          -  Patient informed consent has been obtained [Patients to be enrolled must also provide&#xD;
             voluntary written informed consent to the protocol prior to screening to be eligible&#xD;
             for the study. For adolescents, parent/legal guardian must provide consent and,&#xD;
             wherever possible, patient assent will also be obtained. For compromised patients,&#xD;
             their designated proxy must provide informed consent].&#xD;
&#xD;
          -  Patients willing and able to be hospitalized prior to time of study medication&#xD;
             administration for plasma sampling (5 times during the study).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any other type of congenital or acquired coagulopathy, such as: liver disease&#xD;
             (hepatitis), vitamin k deficiency, uremia, malignancy.&#xD;
&#xD;
          -  Antibodies against Factor VII&#xD;
&#xD;
          -  Ongoing bleeding prophylaxis regimens with AryoSeven/NovoSeven or planned to occur&#xD;
             during the trial&#xD;
&#xD;
          -  Platelet count less than 100.000 platelets/mcL (at screening visit)&#xD;
&#xD;
          -  Any clinical sign or known history of arterial thrombotic event or deep venous-&#xD;
             thrombosis or pulmonary embolism&#xD;
&#xD;
          -  HIV positive with current CD4+ count of less than 200/µL&#xD;
&#xD;
          -  Liver cirrhosis&#xD;
&#xD;
          -  Factor VIII/IX immune tolerance induction regimen planned to occur during the trial&#xD;
&#xD;
          -  Known hypersensitivity to the study medication&#xD;
&#xD;
          -  Parallel participation in another experimental drug trial.&#xD;
&#xD;
          -  Parallel participation in another marketed drug trial that may affect the primary&#xD;
             end-point of the study.&#xD;
&#xD;
          -  Concomitant diseases and/or medications, or any other conditions, that render the&#xD;
             patient unsuitable for inclusion into the study in the judgement of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Iacobelli, MD</last_name>
    <role>Study Director</role>
    <affiliation>Consultant</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amirhossein Saadatirad, PhD</last_name>
    <phone>+98(26)36106480</phone>
    <email>saadatirada@aryogen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Comprehensive Hemophilia Care Center</name>
      <address>
        <city>Teheran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Reza Baghaipour, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 6, 2021</last_update_submitted>
  <last_update_submitted_qc>March 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

